MINIRIN Oral Lyophilisate

ApprovedSmall molecule

Ferring

MINIRIN Oral Lyophilisate is one of 19 small molecule programs targeting Enuresis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EnuresisActive, not recruiting

EnuresisApproved

Active, not recruiting

Competition

Competitive Landscape

26 competitors in Enuresis

#DrugCompanyPhaseTrials

Indocin

LLife Extension Foundation Inc.

Approved

1 2

Pitressin

AAultman Health Foundation

Advil

Myrbetriq

2 5

Prozac

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

2 6

Oxytrol

WWim Janssens

Phase 3

1 7

Circadin

NNeurim Pharmaceuticals Ltd.

Phase 2

1 8

MINIRIN Oral Lyophilisate

Ferring

Approved

1 9

Strattera

MMap77

Phase 1

1 10

Minirin

Ferring

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Enuresis1 trial

A 6-week Open Label Cross-over Study With 2 Different Daily Doses of Minirin® Oral Lyophilisate in Children and Adolescents With Primary Nocturnal Enuresis (PNE)

Completed· Ferring logo

Ferring·Phase 4·NCT00209261·221 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for MINIRIN Oral Lyophilisate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MINIRIN Oral Lyophilisate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MINIRIN Oral Lyophilisate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ferring company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Ferring

MINIRIN Oral Lyophilisate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Enuresis1 trial

References

Drug Info

Quick Facts

Related News